Cargando…

Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders

Recent evidence suggests potential, but unproven, links between dietary, metabolic, infective, and gastrointestinal factors and the behavioral exacerbations and remissions of autism spectrum disorders (ASDs). Propionic acid (PPA) and its related short-chain fatty acids (SCFAs) are fermentation produ...

Descripción completa

Detalles Bibliográficos
Autor principal: MacFabe, Derrick F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747729/
https://www.ncbi.nlm.nih.gov/pubmed/23990817
http://dx.doi.org/10.3402/mehd.v23i0.19260
_version_ 1782280978321899520
author MacFabe, Derrick F.
author_facet MacFabe, Derrick F.
author_sort MacFabe, Derrick F.
collection PubMed
description Recent evidence suggests potential, but unproven, links between dietary, metabolic, infective, and gastrointestinal factors and the behavioral exacerbations and remissions of autism spectrum disorders (ASDs). Propionic acid (PPA) and its related short-chain fatty acids (SCFAs) are fermentation products of ASD-associated bacteria (Clostridia, Bacteriodetes, Desulfovibrio). SCFAs represent a group of compounds derived from the host microbiome that are plausibly linked to ASDs and can induce widespread effects on gut, brain, and behavior. Intraventricular administration of PPA and SCFAs in rats induces abnormal motor movements, repetitive interests, electrographic changes, cognitive deficits, perseveration, and impaired social interactions. The brain tissue of PPA-treated rats shows a number of ASD-linked neurochemical changes, including innate neuroinflammation, increased oxidative stress, glutathione depletion, and altered phospholipid/acylcarnitine profiles. These directly or indirectly contribute to acquired mitochondrial dysfunction via impairment in carnitine-dependent pathways, consistent with findings in patients with ASDs. Of note, common antibiotics may impair carnitine-dependent processes by altering gut flora favoring PPA-producing bacteria and by directly inhibiting carnitine transport across the gut. Human populations that are partial metabolizers of PPA are more common than previously thought. PPA has further bioactive effects on neurotransmitter systems, intracellular acidification/calcium release, fatty acid metabolism, gap junction gating, immune function, and alteration of gene expression that warrant further exploration. These findings are consistent with the symptoms and proposed underlying mechanisms of ASDs and support the use of PPA infusions in rats as a valid animal model of the condition. Collectively, this offers further support that gut-derived factors, such as dietary or enteric bacterially produced SCFAs, may be plausible environmental agents that can trigger ASDs or ASD-related behaviors and deserve further exploration in basic science, agriculture, and clinical medicine.
format Online
Article
Text
id pubmed-3747729
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Co-Action Publishing
record_format MEDLINE/PubMed
spelling pubmed-37477292013-08-29 Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders MacFabe, Derrick F. Microb Ecol Health Dis Thematic Cluster: Focus on Autism Spectrum Disorders Recent evidence suggests potential, but unproven, links between dietary, metabolic, infective, and gastrointestinal factors and the behavioral exacerbations and remissions of autism spectrum disorders (ASDs). Propionic acid (PPA) and its related short-chain fatty acids (SCFAs) are fermentation products of ASD-associated bacteria (Clostridia, Bacteriodetes, Desulfovibrio). SCFAs represent a group of compounds derived from the host microbiome that are plausibly linked to ASDs and can induce widespread effects on gut, brain, and behavior. Intraventricular administration of PPA and SCFAs in rats induces abnormal motor movements, repetitive interests, electrographic changes, cognitive deficits, perseveration, and impaired social interactions. The brain tissue of PPA-treated rats shows a number of ASD-linked neurochemical changes, including innate neuroinflammation, increased oxidative stress, glutathione depletion, and altered phospholipid/acylcarnitine profiles. These directly or indirectly contribute to acquired mitochondrial dysfunction via impairment in carnitine-dependent pathways, consistent with findings in patients with ASDs. Of note, common antibiotics may impair carnitine-dependent processes by altering gut flora favoring PPA-producing bacteria and by directly inhibiting carnitine transport across the gut. Human populations that are partial metabolizers of PPA are more common than previously thought. PPA has further bioactive effects on neurotransmitter systems, intracellular acidification/calcium release, fatty acid metabolism, gap junction gating, immune function, and alteration of gene expression that warrant further exploration. These findings are consistent with the symptoms and proposed underlying mechanisms of ASDs and support the use of PPA infusions in rats as a valid animal model of the condition. Collectively, this offers further support that gut-derived factors, such as dietary or enteric bacterially produced SCFAs, may be plausible environmental agents that can trigger ASDs or ASD-related behaviors and deserve further exploration in basic science, agriculture, and clinical medicine. Co-Action Publishing 2012-08-24 /pmc/articles/PMC3747729/ /pubmed/23990817 http://dx.doi.org/10.3402/mehd.v23i0.19260 Text en © 2012 Derrick F. MacFabe http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Thematic Cluster: Focus on Autism Spectrum Disorders
MacFabe, Derrick F.
Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders
title Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders
title_full Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders
title_fullStr Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders
title_full_unstemmed Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders
title_short Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders
title_sort short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders
topic Thematic Cluster: Focus on Autism Spectrum Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747729/
https://www.ncbi.nlm.nih.gov/pubmed/23990817
http://dx.doi.org/10.3402/mehd.v23i0.19260
work_keys_str_mv AT macfabederrickf shortchainfattyacidfermentationproductsofthegutmicrobiomeimplicationsinautismspectrumdisorders